跳至主要内容
临床试验/NL-OMON52017
NL-OMON52017尚未招募3 期

Patients with axial spondyloarthritis and high disease activity treating with systemic glucocorticoids: a double-blinded randomised controlled trial - Intramuscular glucocorticoid for axial spondylarthritis (SPADE study)

Franciscus Gasthuis & Vlietland0 个研究点目标入组 38 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
38

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Meeting the ASAS classification criteria for axial spondylarthritis
  • Age 18-64 years
  • ASDAS >=2.1
  • Failure of standard treatment, meaning
  • - taking two different NSAIDs in maximum dosage over 4 weeks in total; or
  • - use of the same biological for at least 12 weeks
  • Ability to independently answer Dutch questionnaires
  • Given informed consent

排除标准

  • Starting or switching a biological <12 weeks ago
  • Concomitant disease that requires treatment with systemic GC (e.g. malignancy,
  • chronic obstructive pulmonary disease)
  • Absolute contra-indications for corticosteroids (e.g. systemic infection,
  • peptic ulcer disease)
  • Allergy to corticosteroids
  • Diabetes mellitus
  • Pregnancy or lactating female
  • Cognitive impairment
  • Participation in other medical trial
  • Language barrier

研究者

相似试验